Apyx Medical Corporation Common Stock
APYXApyx Medical Corporation (APYX) develops and markets medical devices, primarily focusing on advanced tissue and nerve ablation techniques. The company's flagship product, Renuvion/JPlasma, uses cold plasma technology for cosmetic skin tightening, body contouring, and minimally invasive surgical procedures, promoting tissue coagulation and rejuvenation. Apyx aims to enhance aesthetic and surgical outcomes through innovative energy-based platforms.
Company News
Apyx Medical announced publication of clinical data demonstrating that a combination treatment approach using Avéli® for subcision and Renuvion® for plasma radiofrequency energy shows significant improvement in cellulite and skin laxity. In a study of 22 patients, 81.8% showed improvement in cellulite appearance at 180 days post-treatment, wit...
Apyx Medical received FDA 510(k) clearance to add power liposuction capability to its AYON Body Contouring System, an advanced liposuction modality using reciprocating cannulas to improve surgical efficiency. The company plans a limited commercial launch to work with early adopters before broader scaling. This expansion positions AYON as a compre...
Apyx Medical Corporation has priced a public offering of 2,762,431 shares of common stock at $3.62 per share, expecting to raise approximately $10 million for working capital and general corporate purposes.
Apyx Medical Corporation received FDA clearance for its AYON Body Contouring System, which combines multiple technologies for body contouring procedures. The company plans to launch the system with key surgeons in the second half of 2025.
Apyx Medical Corporation has submitted a 510(k) premarket notification to the FDA for its AYON Body Contouring System, which is designed to provide comprehensive body contouring solutions through an all-in-one platform.
